These authors found that PD-L1-positive tumors were more likely to have adverse pathological features including a late tumor stage (III or IV), high International Society of Urological Pathology (ISUP) grade (III or IV), larger tumor size, and a higher risk of cancer-specific mortality for patients. The gene discussed is CD274; the disease is cancer.